In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F23%3A43925984" target="_blank" >RIV/00064173:_____/23:43925984 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/23:43925984 RIV/75010330:_____/23:00014406

Výsledek na webu

<a href="https://doi.org/10.1089/mdr.2023.0090" target="_blank" >https://doi.org/10.1089/mdr.2023.0090</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1089/mdr.2023.0090" target="_blank" >10.1089/mdr.2023.0090</a>

Jazyk výsledku

angličtina

Název v původním jazyce

In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa

Popis výsledku v původním jazyce

The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order Enterobacterales, and 40 strains of Pseudomonas aeruginosa. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (bla(KPC), bla(OXA-48), bla(NDM), bla(VIM), bla(IMP), bla(GES)) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (n = 149) strains of the order Enterobacterales and 77.5% (n = 31) of P. aeruginosa isolates were inhibited at minimal inhibitory concentration (MIC) &lt;=2 mg/L. Values MIC(50)/MIC(90) were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for P. aeruginosa. One isolate (Klebsiella pneumoniae) harboring two carbapenemases (bla(OXA-48), bla(NDM)) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, bla(NDM) carbapenemase prevailed (43.3%, n = 29), followed by bla(OXA-48) (31.3%, n = 21) and bla(KPC) (4.5%, n = 3). bla(IMP) (n = 8) and bla(VIM) (n = 1) metallo-β-lactamases dominated in cefiderocol-resistant P. aeruginosa (n = 9) isolates. Very good susceptibility (100%) to this drug showed bla(GES)-positive strains of P. aeruginosa (n = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (n = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.

Název v anglickém jazyce

In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa

Popis výsledku anglicky

The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order Enterobacterales, and 40 strains of Pseudomonas aeruginosa. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (bla(KPC), bla(OXA-48), bla(NDM), bla(VIM), bla(IMP), bla(GES)) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (n = 149) strains of the order Enterobacterales and 77.5% (n = 31) of P. aeruginosa isolates were inhibited at minimal inhibitory concentration (MIC) &lt;=2 mg/L. Values MIC(50)/MIC(90) were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for P. aeruginosa. One isolate (Klebsiella pneumoniae) harboring two carbapenemases (bla(OXA-48), bla(NDM)) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, bla(NDM) carbapenemase prevailed (43.3%, n = 29), followed by bla(OXA-48) (31.3%, n = 21) and bla(KPC) (4.5%, n = 3). bla(IMP) (n = 8) and bla(VIM) (n = 1) metallo-β-lactamases dominated in cefiderocol-resistant P. aeruginosa (n = 9) isolates. Very good susceptibility (100%) to this drug showed bla(GES)-positive strains of P. aeruginosa (n = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (n = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30304 - Public and environmental health

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Microbial Drug Resistance

ISSN

1076-6294

e-ISSN

1931-8448

Svazek periodika

290

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

485-491

Kód UT WoS článku

001085013900006

EID výsledku v databázi Scopus

2-s2.0-85170686816